Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial

What this study is testing ClinicalTrials.gov NCT07732218 ↗

Description as written by the study sponsor.

A single arm no randomized clinical trial evaluated the effectiveness and safety of once weekly semaglutide in adults with type 2 diabetes militus and obesity whose glycemic control remained inadequate despite standard therapy. participants received semaglutide for 16 weeks, beginning with 0.25mg weekly for 4 weeks followed by 0.5 mg weekly for 12 weeks. the primary outcome was the change in glycated hemoglobin, while secondary outcomes included changes in body weight, body mass index, blood glucose, blood pressure, lipid profile and treatment related adverse effects.

Treatments tested

• Semaglutide (Ozempic®) Drug

  participants received semaglutide by subcutaneous injection once weekly for 16 weeks. smaglutide was initiated at 0.25mg once weekly for the first 4 weeks, followed by 0.5mg once weekly for the subsequent 12 weeks